Allogeneic mesenchymal stem cells have been used in a number of clinical trials for different indications. These clinical trials demonstrated the safety of allogeneic mesenchymal stem cell application. Mironov, M.D., Chief of Neurology, President’s Kremlin Hospital Treatment in Moscow treated over a thousand patients with neurodegenerative diseases with allogeneic mesenchyman and neuronal cells. Cell used by Dr. Mirinov were prepared by a patented method and adopted by Stemedica for production of mesenchymal cells which were used in pre-clinical trials to study toxicity and tumorigenecity as reported below.
Cells (spelled “cell” in article) used by Dr. Mirinov were prepared by Stemedica using a patented method for production of mesenchymal cells which were used in pre-clinical trials to study toxicity and tumorigenecity.
During the clinical trials, 19 US patients traveled to Moscow to receive treatment with mesenchymal and neuronal cells for a number of conditions including: stroke, Alzheimer’s Disease, Parkinson’s Disease, spinal cord injury, autism, lupus, congenital cerebral palsy, muscular dystrophy, and hearing loss. All patients signed informed consent waivers before the treatment.
Each patient received one to four treatments from 2006 to 2009 using mesenchymal and neuronal stem cells. During this time, only two adverse events were reported: one case of painful sensation (2 out of 10) in the spinal area because of spinal puncture and one case of slight fever two days post treatment. Improvement in patient status was reported in 17 out of 19 (89%) patients. None of the patients developed tumors.